• Biosimilars
  • Drug Development/R&D
  • All Topics
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies

CombTher_Adobe_photoguns_portrait
Read more
© photoguns
  • Digital Health

Navigating the Landscape of Digital Health – United Kingdom

Healthcare_Adobe_elenabsl
Read more

2021 OHE Annual Report to the Charity Commission

charityreport_lina-trochez-unsplash_landscape
Read more
© Lina Trochez/Unsplash

Supporting the Era of Green Pharmaceuticals in the UK

Sustainability_AdobeStock_270582392_landscape
Read more

Quality of life and wellbeing in individuals with experience of fertility problems and assisted reproductive techniques

Quality of life assisted reproduction Cover
Read more
  • Cell and Gene Therapies
  • Value, Affordability, and…

Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?

gene_therapies_national-cancer-institute-unsplash_landscape
Read more
© NCI/Unsplash
  • Drug Development/R&D
  • Economics of Innovation
  • Health Policy and Regulation

Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

CBO-US_mayer-tawfik-K4Ckc0AxgDI-unsplash_landscape
Read more
© Mayer Tawfik/Unsplash
  • Measuring and Valuing Outcomes

When Generic Measures Fail to Reflect What Matters to Patients: Three Case Studies

PROMS_unsplash_National Cancer Institute_landscape
Read more
© NCI/Unsplash
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • News
11 min read 12th May 2015

OHE at ISPOR Philadelphia Part 2: Risk Sharing, Medical Breakthroughs, Early Access and Drug Development Costs

This post is the second of a two part summary of OHE’s scheduled activity at ISPOR Philadelphia 2015. ISPOR’s 20th Annual International Meeting is scheduled for 16-20 May 2015 in Philadelphia. This post is the second of a two part…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email

This post is the second of a two part summary of OHE’s scheduled activity at ISPOR Philadelphia 2015.

ISPOR’s 20th Annual International Meeting is scheduled for 16-20 May 2015 in Philadelphia. This post is the second of a two part summary of OHE’s scheduled activity at ISPOR. Access the first blog post here.

Risk Sharing / Performance-Based Arrangements for Drugs and Other Medical Products
 
Lou Garrison (University of Washington), Adrian Towse (OHE), Josh Carlson (University of Washington). 
 
This short course will explore the theory and practice behind risk sharing and performance based arrangements (PBRSAs), including trends, and the challenges involved in putting them in place. Several examples of performance-based schemes from Europe, the United States, and Australia will be analysed.
 
Prior registration is required.
 
Sunday 17 May
8:00 AM – 12:00 PM
 
Can we afford medical breakthroughs for large prevalence diseases? Lessons from hepatitis C
 
Moderator: Dana Goldman (University of Southern California). Panelists: Adrian Towse (OHE), Ross Maclean (Precision Health Economics), Thomas Philipson (University of Chicago).
 
This panel will discuss how the financial burden of highly effective treatments can hinder reimbursement (as seen recently in the case of hep C). Policy, industry and health economics perspectives will be represented. The panel will consider how to align the costs and benefits of such medical breakthroughs, the role of credit markets, and lessons learned from hep C.
 
Monday 18 May, Issue panels – session II
11:00 AM – 12:00 PM
 
Early access to medicines: What is in it for payers?
 
Moderator: Adam Heathfield (Pfizer). Panelists: Adrian Towse (OHE), Mark Trusheim (Massachusetts Institute of Technology), Dan Ollendorf (Institute for Clinical and Economic Review).
 
This panel will consider the potential benefits and costs of early access to new medicines for payers. The group will discuss new modelling work to show the potential benefits, as well as the use of value initiatives and pilot schemes.
 
Tuesday 19 May, Issue panels – session II
11:00 AM – 12:00 PM
 
The $2.6 billion question: Why are drug development costs rising and can we afford it? (Invited Issue Panel)
 
Moderator: Lou Garrison (University of Washington). Panelists: Adrian Towse (OHE), Joseph DiMasi (Tufts University), Patricia Danzon (University of Pennsylvania).
 
DiMasi will present new evidence which suggest that drug development costs an average of $2.6 billion per approved new compound. The panel will discuss the implications of this for drug development, further research and policy, and comment on the need for a new drug development paradigm.
 
Tuesday 19 May, Issue panels – session III
2:15 PM – 3:15 PM
 
  • Drug Development/R&D
  • Presentations

Related News

  • News
  • September 2020

Cornerstones of ‘Fair’ Drug Coverage

Read more
  • News
  • September 2020

Establishing a Reasonable Price for an Orphan Drug

Read more
  • News
  • June 2020

The 2020 OHE Annual Lecture Explores the Question: How Should the World Pay for a COVID-19 Vaccine?

Read more
Danzon_Patricia_1305 (1)
  • News
  • June 2020

Victor R. Fuchs Award for 2020 Goes to Patricia Danzon

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!